A license agreement between USA-based Novavax (Nasdaq: NVAX) and the Serum Institute of India will provide for wider access to NVX‑CoV2373, the firm’s COVID‑19 vaccine.
The deal allows for development and commercialization of the vaccine candidate India and other low- and middle-income countries, building on an existing collaboration with the Coalition for Epidemic Preparedness Innovations (CEPI).
The organizations will work together on clinical development, co-formulation, filling and finishing and commercialization, while the Serum Institute will be responsible for regulatory submissions and marketing authorizations.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze